Fidia to Introduce Hymovis, Next-Generation Hyaluronan

At AAOS 2016, Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain following an inadequate response to conservative non-pharmacologic therapy or analgesics.

FDA granted premarket approval to Hymovis in 3Q15.

Source: Fidia Farmaceutici S.p.A.



document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us